-
-
-
-
-
-
-
BeyondSpring (BYSI) Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel
-
-
-
-
-
418,155 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

